Montwill J, Igoe D, McKenna T J
Department of Endocrinology and Diabetes Mellitus, St. Vincent's Hospital, Dublin, Ireland.
Steroids. 1994 May;59(5):296-8. doi: 10.1016/0039-128x(94)90116-3.
This study was undertaken to examine the performance of the overnight dexamethasone test, i.e., plasma cortisol level at 8-9 AM following dexamethasone 1 mg by mouth at midnight, in screening for Cushing's syndrome. The participants included 19 patients with Cushing's syndrome (17 with Cushing's disease, 1 with adrenal carcinoma, and 1 with ectopic ACTH syndrome) and 96 patients in whom the possibility of Cushing's syndrome was raised but who did not have the disorder. Utilizing our original very conservative cutoff point of plasma 100 nmol/L (3.62 micrograms/dL) above which Cushing's syndrome was suspected, the sensitivity of the test was 100% but the false positive rate was an unsatisfactory 12.5%. However, the lowest plasma cortisol level achieved following the overnight dexamethasone test in patients with Cushing's syndrome was 259 nmol/L (9.39 micrograms/dL). A plasma cortisol cutoff point of 250 nmol/L (9.06 micrograms/dL) yielded no false negatives and the false positive rate fell to 6.25%. Using a cutoff point of 200 nmol/L (7.24 micrograms/dL) the false positive rate was 7.3%. These performance characteristics of the overnight dexamethasone test compare very favorably with the reported experience of all other screening procedures for Cushing's syndrome including the urinary free cortisol excretion rate and the 48 h dexamethasone test, while the overnight dexamethasone procedure is the simplest for both patients and medical personnel. Since it is possible that some very unusual patients may suppress to plasma cortisol levels lower than that seen in the present study, we now recommend the overnight dexamethasone test using a plasma cortisol cutoff point of 200 nmol/L as the procedure of choice when screening for patients with Cushing's syndrome.
本研究旨在检测午夜口服1毫克地塞米松后,上午8 - 9点血浆皮质醇水平的过夜地塞米松试验在库欣综合征筛查中的表现。参与者包括19例库欣综合征患者(17例库欣病、1例肾上腺皮质癌和1例异位促肾上腺皮质激素综合征)以及96例库欣综合征可能性增加但未患该疾病的患者。采用我们最初设定的非常保守的血浆100纳摩尔/升(3.62微克/分升)的临界值,高于此值怀疑为库欣综合征,该试验的敏感性为100%,但假阳性率高达12.5%,不尽人意。然而,库欣综合征患者过夜地塞米松试验后达到的最低血浆皮质醇水平为259纳摩尔/升(9.39微克/分升)。血浆皮质醇临界值设定为250纳摩尔/升(9.06微克/分升)时无假阴性,假阳性率降至6.25%。使用200纳摩尔/升(7.24微克/分升)的临界值时,假阳性率为7.3%。过夜地塞米松试验的这些表现特征与包括尿游离皮质醇排泄率和48小时地塞米松试验在内的所有其他库欣综合征筛查程序的报道经验相比非常有利,同时过夜地塞米松程序对患者和医务人员来说都是最简单的。由于可能存在一些非常特殊的患者,其血浆皮质醇水平的抑制程度可能低于本研究中的情况,我们现在推荐将血浆皮质醇临界值设定为200纳摩尔/升的过夜地塞米松试验作为筛查库欣综合征患者时的首选方法。